These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 32749708)

  • 1. Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?
    Campana P; Flocco V; Aruta F; Cacciatore F; Abete P
    J Med Virol; 2021 Feb; 93(2):622-623. PubMed ID: 32749708
    [No Abstract]   [Full Text] [Related]  

  • 2. Guillain Barré syndrome and COVID-19: Possible role of the cytokine storm.
    Hussain FS; Eldeeb MA; Blackmore D; Siddiqi ZA
    Autoimmun Rev; 2020 Dec; 19(12):102681. PubMed ID: 33099040
    [No Abstract]   [Full Text] [Related]  

  • 3. Is IL-6 a key cytokine target for therapy in COVID-19?
    Jones SA; Hunter CA
    Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulated miR-451a as a feature of the plasma cfRNA landscape reveals regulatory networks of IL-6/IL-6R-associated cytokine storms in COVID-19 patients.
    Yang P; Zhao Y; Li J; Liu C; Zhu L; Zhang J; Yu Y; Wang WJ; Lei G; Yan J; Sun F; Bian C; Meng F; Xu Z; Bai C; Ye B; Guo Y; Shu L; Yuan X; Zhang N; Bi Y; Shi Y; Wu G; Zhang S; Gao GF; Liu L; Liu WJ; Sun HX
    Cell Mol Immunol; 2021 Apr; 18(4):1064-1066. PubMed ID: 33637960
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19, Guillain-Barré syndrome, and the vaccine. A dangerous combination.
    Aomar-Millán IF; Martínez de Victoria-Carazo J; Peregrina-Rivas JA; Villegas-Rodríguez I
    Rev Clin Esp (Barc); 2021 Nov; 221(9):555-557. PubMed ID: 34593364
    [No Abstract]   [Full Text] [Related]  

  • 6. Spectrum of Neurological Manifestations in Covid-19: A Review.
    Garg RK
    Neurol India; 2020; 68(3):560-572. PubMed ID: 32643664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the Human Cytokine Response from Acute Illness to Disease Resolution in SARS-Cov-2 Infection-Implications for Therapeutic Monitoring and Therapeutic Targets.
    Drewett GP; Copaescu A; Mouhtouris E; Hannan N; James F; Smibert O; Holmes NE; Trubiano JA
    J Clin Immunol; 2021 Aug; 41(6):1162-1164. PubMed ID: 33864183
    [No Abstract]   [Full Text] [Related]  

  • 8. The emergence of a new cytokine storm during the COVID-19 pandemic: Multisystem inflammatory syndrome in children.
    Yang MC; Tsai CC; Su YT; Wu JR
    Kaohsiung J Med Sci; 2021 Mar; 37(3):255-256. PubMed ID: 33400372
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Responses to the Novel Coronavirus-2: Friend or Foe?
    Mahmoodpoor A; Nader ND
    Immunol Invest; 2021 Nov; 50(8):949-951. PubMed ID: 32689852
    [No Abstract]   [Full Text] [Related]  

  • 10. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome.
    Chen LYC; Biggs CM; Jamal S; Stukas S; Wellington CL; Sekhon MS
    Cell Rep Med; 2021 May; 2(5):100269. PubMed ID: 33899032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guillain-Barré syndrome associated with SARS-CoV-2].
    Chapon F
    Med Sci (Paris); 2020 Dec; 36 Hors série n° 2():53-54. PubMed ID: 33427637
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical Reasoning: A case of COVID-19-associated pharyngeal-cervical-brachial variant of Guillain-Barré syndrome.
    Liberatore G; De Santis T; Doneddu PE; Gentile F; Albanese A; Nobile-Orazio E
    Neurology; 2020 Nov; 95(21):978-983. PubMed ID: 32917799
    [No Abstract]   [Full Text] [Related]  

  • 13. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
    Smetana K; Brábek J
    In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Suspected Donor-derived Human Herpesvirus-8 Infection in a Liver Transplant Patient With Coronavirus Disease-19.
    Peri AM; Magro B; van den Bogaart L; Dalla Pria A; Giuffrida P; Gianatti A; Fabretti F; Maria Barbui A; Tebaldi A; Rizzi M; Fagiuoli AS
    Transplantation; 2021 Jun; 105(6):e65-e67. PubMed ID: 34048423
    [No Abstract]   [Full Text] [Related]  

  • 17. Motor unit electrophysiological changes in Guillain-Barré syndrome in the context of a COVID-19 infection.
    Garnés-Camarena O; Díaz-Cano G; Stashuk D
    Muscle Nerve; 2021 Nov; 64(5):E23-E25. PubMed ID: 34448233
    [No Abstract]   [Full Text] [Related]  

  • 18. Guillain-Barré syndrome is immunogenic in SARS-CoV-2 infected.
    Finsterer J; Almas T
    J Med Virol; 2022 Jan; 94(1):22-23. PubMed ID: 34468997
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic inflammation as fuel for acute liver injury in COVID-19.
    Effenberger M; Grander C; Grabherr F; Griesmacher A; Ploner T; Hartig F; Bellmann-Weiler R; Joannidis M; Zoller H; Weiss G; Adolph TE; Tilg H
    Dig Liver Dis; 2021 Feb; 53(2):158-165. PubMed ID: 32873520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Interleukin-10 Levels in COVID-19: Potentiation of Pro-Inflammatory Responses or Impaired Anti-Inflammatory Action?
    Islam H; Chamberlain TC; Mui AL; Little JP
    Front Immunol; 2021; 12():677008. PubMed ID: 34234779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.